4D Molecular Therapeutics, Inc. Cash Flow Statement
FDMT|6 years of annual SEC 10-K data (FY2020-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 6 fiscal years. All figures from audited SEC 10-K filings.
4D Molecular Therapeutics, Inc. used $135M in operating cash flow and negative free cash flow of $138M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 3.26 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Net Income | -$160.9M | -$100.8M | -$107.5M | -$71.3M | -$56.7M | -$49.3M |
| Depreciation & Amortization | $4.7M | $4.2M | $2.4M | $1.5M | $1.4M | $1.0M |
| Operating Cash Flow | -$134.6M | -$75.8M | -$86.7M | -$69.1M | -$50.9M | -$36.7M |
| Capital Expenditures | $3.8M | $2.8M | $11.5M | $9.1M | $1.0M | $3.2M |
| Free Cash Flow | -$138.4M | -$78.6M | -$98.2M | -$78.2M | -$51.9M | -$39.9M |
| FCF Margin | -373975.7% | -379.1% | -3139.0% | -433.8% | -381.3% | -571.3% |